170 results about "Hypertension treatment" patented technology

Treatment of hypertension includes implantation of the discharge portion(s) of a catheter and / or electrical stimulation electrode(s) adjacent the tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and / or electrical pulses, are supplied by one or more implanted stimulators, through the catheter and possibly also a lead, tunneled subcutaneously between the stimulator and stimulation site. A microstimulator(s) may also / instead deliver electrical stimulation pulses. Stimulation sites include the carotid sinus and carotid body, among other locations. Treatments include drugs used for acute and / or chronic treatment of hypertension. In a number of embodiments, a need for or response to treatment is sensed, and the electrical and / or infusion pulses adjusted accordingly.

The present invention relates to methods for the diagnosis and evaluation of cardiovascular illness, particularly stroke, myocardial and other cardiovascular damage damage, hypertension treatment. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for cardiovascular illness or hypertension treatment and one or more non-specific markers for cardiovascular illness or hypertension treatment. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. Algorithms for determining proper treatment are disclosed. A diagnostic kit for a panel of said markers is disclosed. In various aspects, the invention provides methods for the early detection and differentiation of cardiovascular illness or hypertension treatment. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

A method and device for delivering and monitoring baroreflex and drug therapy to manage hypertension. The method includes providing an implanted an implanted medical device configured to automatically detect drug-related effects on the autonomic nervous system including the steps of measuring a physiologic status of the autonomic nervous system at desired intervals, logging the physiologic status of the autonomic nervous system at desired intervals, monitoring the measured and logged physiologic status of the autonomic nervous system for any changes and correlating the changes to a corresponding drug administration time. The device includes an implanted baroreflex activation device capable of administering one or more hypertension treatment drugs including a controller that activates and adjusts therapy delivery, a baroreflex activation therapy delivery device, a drug therapy delivery device and a device that senses physiologic parameters.

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and / or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.

Configurations are described for utilizing light-activated proteins within cell membranes and subcellular regions to assist with medical treatment paradigms, such as hypertension treatment via anatomically specific and temporally precise modulation of renal plexus activity. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-sensitive proteins to specific cells or defined cell populations. In particular the invention provides systems, devices, and methods for millisecond-timescale temporal control of certain cell activities using moderate light intensities, such as the generation or inhibition of electrical spikes in nerve cells and other excitable cells.

The invention, which belongs to the medical instrument filed, relates to a multifunctional hypertension therapeutic instrument, which is used for hypertension treatment by a hypertension patient herself / himself in daily life. The multifunctional hypertension therapeutic instrument is in a mini portable type and can be worn by a user in daily life. The multifunctional hypertension therapeutic instrument comprises a hypertension treatment mode portion, a step count mode portion, a respiration sensor and an electrode. According to the invention, a respiratory rhythm signal of a hypertension patient is utilized as a biofeedback signal in a hypertension treatment mode, wherein the respiratory rhythm signal is detected by a novel respiration sensor; a core control module controls a simulation signal generation module to generate a low-frequency electric simulation signal that is used for guiding breathing of a patient; and the low-frequency electric simulation signal is transmitted to the patient by the electrode and guides the patient to breathe slowly. Storage and statistics are carried out on daily walking data of a user in a step count mode. The multifunctional hypertension therapeutic instrument provided in the invention has advantages of portability, low cost, and simple usage; moreover, the instrument enables hypertension to be effectively reduced.

Systems, methods, and devices for treating pulmonary arterial hypertension are provided. The system comprises an implantable actuator that compresses the pulmonary artery.

The invention relates to a Chinese medicine preparation for treating hypertension. The Chinese medicine preparation is characterized by being prepared from the following bulk pharmaceutical chemicals in parts by weight: 12-18 parts of radix astragali, 12-18 parts of concha haliotidis, 10-14 parts of apocynum venetum, 10-14 parts of radix scrophulariae, 10-14 parts of semen cassiae, 12-18 parts of roots bark of white mulberry, 12-18 parts of honeysuckle, 12-18 parts of dried rehmannia roots, 5-9 parts of radix puerariae, 2-4 parts of rhizoma coptidis, 5-9 parts of rhubarb, 4-6 parts of radix bupleuri, 2-4 parts of fossil fragments, 12-18 parts of magnetite, 10-14 parts of hawthorn, 12-18 parts of selfheal, 4-6 parts of motherwort, 5-9 parts of fruits of Chinese wolfberry, 4-6 parts of sophora flowers, 5-9 parts of radix cynanchi atrati, 4-6 parts of dried lily bulbs and 5-9 parts of lotus seeds. The Chinese medicine preparation disclosed by the invention has the advantages of distinct curative effect, small side effects, simplicity in preparation and low cost; and through clinical validation, the effective hypertension treatment rate of the Chinese medicine preparation disclosed by the invention is 99%.

The invention discloses an ACE inhibitory peptide and a preparation method and application. The amino acid sequence of the ACE inhibitory peptide is GPPGP and is derived from natural animal proteins,the IC50 of the ACE inhibitory peptide is 190.43 micromole per liter, the molecular weight is small, and the ACE inhibitory peptide has the advantages of being stable, safe, easy to absorb by the human body and the like and can be used for industrial production. The ACE inhibitory peptide with the amino acid sequence of GPPGP can be used for preparing hypertension treatment / prevention medicine orserving as a functional food additive for long-term treatment and health care of hypertension patients.

Methods and therapeutic combinations are provided for lowering blood pressure in a subject exhibiting resistance to a baseline antihypertensive therapy with one or more drugs, or a subject having diabetes and / or chronic kidney disease. A method of the invention comprises administering, in some embodiments adjunctively with a modified baseline therapy, a compound of formula (I) as defined herein. A therapeutic combination of the invention comprises a compound of formula (I); at least one diuretic; and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers; wherein the at least one diuretic and / or the at least one antihypertensive drug are present at substantially less than a full dose.

The invention relates to the field of hypertension treatment medicinal preparations, and provides an enalapril maleate tablet composition. The enalapril maleate tablet composition comprises enalapril maleate as an active component, one or more organic acids and auxiliary materials. The enalapril maleate tablet composition is characterized in that the one or more organic acids selected from malic acid, tartaric acid and taurine. The enalapril maleate tablet composition improves greatly enalapril maleate tablet storage stability, guarantees medical efficacy and reduces toxicity.

The invention discloses a pharmaceutical composition of amrinone and application of the pharmaceutical composition in hypertension treatment. Amrinone and a novel-structure natural product compound (I) separated out of dried rhizomes of blackberry lily are contained in the pharmaceutical composition of amrinone, and when amrinone and the natural product compound (I) act independently, the treatment effect on renal vascular hypertension is achieved; when amrinone and the natural product compound (I) act jointly, the treatment effect on renal vascular hypertension is further improved, the pharmaceutical composition can be developed into medicine for treating renal vascular hypertension, and compared with the prior art, prominent substantive features and remarkable progress are achieved.

The invention provides clonidine hydrochloride sustained release pellets. The clonidine hydrochloride sustained release pellets comprise medicine-containing pellets and enteric coating layers, wherein the medicine-containing pellets are coated by the enteric coating layers; the medicine-containing pellets comprise 0.1mg of clonidine hydrochloride, 180mg of hollow pellet cores and 10mg of adhesive; the enteric coating layers comprise 45-225mg of Eudragit NE30D and 7-68mg of talcum powder. A preparation method of the clonidine hydrochloride sustained release pellets comprises the following processes: 1. material preparation; 2. pellet preparation; 3. preparation of an enteric coating agent; 4. coating; 5. filling; 6. aluminium-plastic packaging and preparation of finished products. The sustained release pellets with clonidine hydrochloride as an active ingredient are mainly used for treating hypertension and have the beneficial effects that as the two kinds of advanced technologies, namely novel sustained release preparations and pellet preparations, are adopted, the clonidine hydrochloride sustained release pellets have stable treatment effects and higher bioavailability and have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like. The preparation method is simple and practicable and is suitable for industrial production.

The invention discloses a Chinese herbal medicine for hypertension treatment, aiming at solving the problem of low therapeutic effect of prior art, comprising the following raw materials largehead atractylodes rhizome 15g, licorice 25g, notopterygium incisium 25g, atractylodes 20g, angelica sinensis 20g, officinal magnolia bark 6g, bupleurum 25g, rhiaoma liguistici 15g, astragalus 20g, atractylodes 6g, plaster 10g, pinellia ternate 5g, arisaema cum bile 6g, green tangerine peel 10g, weeping forsythia 20g, cassia seed 10g, herba equiseti hiemalis 20g, puncturevine caltrop fruit 20g, squama manis 5g, cyathula root 10g, common selfheal 15g, pollen 15g, radish seed 10g, medicated leaven 10g, skunk bugbane 15g, Chinese rhubarb 10g, fineleaf schizonepeta herb 15g; which has the functions of eliminating phlegm and promoting blood circulation, and regulating the flow of vital energy to discharge the impurity or toxic impurity in the intestine, normalize blood pressure and promote healthy.

The invention discloses a mussel protein antihypertensive peptide with an antihypertensive activity as well as a preparation method and an application thereof. The amino acid sequence of the antihypertensive peptide is Val-Ser-Trp-Pro-Cys-Arg-Trp (VSWPCRW), and the molecular weight measured by ESI-MS is 935.07 Da. The active peptide Val-Ser-Trp-Pro-Cys-Arg-Trp (VSWPCRW) is obtained through shelling and meat taking, enzymolysis, ultrafiltration, agarose magnetic microsphere immobilized ACE adsorption and reversed-phase high-performance liquid chromatography (RP-HPLC) purification. The active peptide prepared by the preparation method disclosed by the invention is remarkable in angiotensin converting enzyme (ACE) inhibitory activity, and capable of being used for hypertension treatment-related medicines.

The present invention relates to an induced hepatic stem cell defined as follows, a process for production thereof, and applications of the cell, which are useful in safety tests, toxicity tests, metabolism tests, drug interaction tests, antiviral activity tests, screening tests for pharmaceuticals such as hyperlipidemic therapeutics, hypertension therapeutics, low-molecular weight compound medicaments, and antibody medicaments, screening for targets in drug discovery, preparation of animal models, production of hepatocyte-produced proteins, and in regenerative medicine. The induced hepatic stem cell of the present invention is characterized by at least satisfying the following requirements (1)-(3): (1) it expresses at least 15 genes as selected from the group of the genes which are marker genes for an embryonic stem cell; (2) it has properties of a hepatocyte; and (3) it can be subjected to expansion culture or passage culture for at least 3 days.

The invention discloses a traditional Chinese medicinal composition for treating hypertension. The traditional Chinese medicinal composition is prepared by using the following raw materials, by weight, 15-20 parts of Gynostemma pentaphylla, 10-15 parts of Apocynum venetum, 10-15 parts of honeysuckle flower, 10-15 parts of cassia seed, 10-15 parts of Gambir Plant, 10-15 parts of Aristolochia contorta Bunge, 10-15 parts of epimedium, 15-20 parts of Gentiana scabra Bunge, 15-20 parts of Platycladi Seed, 15-20 parts of Spica Prunellae, 10-15 parts of white peony root, 15-20 parts of Salvia miltiorrhiza, 10-15 parts of Herba Siegesbeckiae, 15-20 parts of Chinese Taxillus Twig and 15-20 parts of Clerodendrum trichotomum Thunb. The composition has no toxic side effects on hypertension treatment, is harmless to the heart, the brain and the kidney, and can clear blood toxins, improve microcirculation, prevent and treat complications, simultaneously treat principal and subordinate symptoms and treat hypertension fundamentally.

The invention discloses angiotensin converting enzyme (ACE) inhibitory peptide which has specific sequence and is screened from porphyra haitanensis enzymolysis products. The sequence of the polypeptide is Thr-Gly-Ala-Pro-Cys-Arg (TGAPCR), and through mass spectrum identification, the molecular weight of the polypeptide is 603.69 Da. The polypeptide has the characteristics of stable structure, notoxicity, high water solubility and the like; and through in-vitro high-performance liquid chromatography (HPLC) identification, the polypeptide has low IC50. Significant effect of reducing the systolic pressure of spontaneously hypertensive rats in vivo is achieved; and the diastolic pressure can be reduced for a long time. The ACE inhibitory peptide with specific sequence can be applied to development of an ACE inhibitor and also can be applied to health-care products and medicine products related to hypertensive therapy.

The traditional Chinese medicine nursing smashing device comprises a first box body and a plurality of supporting legs arranged at the lower end of the first box body, a second box body communicating with an inner cavity of the first box body is arranged in the middle of the upper end of the first box body, and a feeding groove used for feeding is formed in the outer side of the second box body; a feeding groove is formed in the outer side of the first box body, the feeding groove is annularly formed, a filtering ring net used for conducting preliminary screening on medicine is distributed on the outer side of the second box body, a smashing shaft is arranged between the first box body and the second box body, a fourth gear is arranged at the upper end of the smashing shaft, and a steering ring plate is rotationally arranged on the outer side of the upper end of the second box body; the screening device is designed according to existing requirements, medicinal materials can be pre-crushed so that the medicinal materials can be in a state suitable for grinding, the grinding efficiency can be improved, the surface of a screening face can be disturbed while grinding is conducted, reverse blowing operation can be conducted on the lower portion of the screening face, screening blockage is effectively avoided, and the screening efficiency is guaranteed.

The patent of the invention designs a respiratory rhythm detection sensor for a slow breathing training blood pressure therapeutic instrument. The principle that the abdominal cavity volume changes rhythmically along with respiration of a human body is designed and utilized, the pressure change, caused by the abdominal cavity volume change, of the sensor can be converted into a rhythmic electric signal through a bridge circuit composed of an elastic element and a strain gauge, and therefore the purpose of measuring the respiratory rate is achieved.

The invention discloses a hypertension treatment medicine. The medicine is prepared through using the following raw medicines, by weight, 1-15 parts of Spica Prunellae, 1-14 parts of wild chrysanthemum flower, 1-20 parts of Gambir Plant and 1-15 parts of Galeobdolon chinense. Compared with the prior art, the medicine has the advantages of blood circulation invigorating, stasis transforming, phlegm reducing, vein relaxing, qi moving, pain relieving, yin nourishing, heat clearing, vexation eliminating, nerve calming and blood pressure adjusting to normalize the blood pressure. Years of exploitation researches and clinic use show that the medicine prepared through refining Chinese herbal medicines has a good effect and makes the recurrence of the hypertension difficult.

The invention provides a compound prepared from an angiotensin receptor antagonist and an enkephalinase inhibitor and application of the compound. The compound is prepared from the angiotensin receptor antagonist and the enkephalinase inhibitor, the angiotensin receptor antagonist and the enkephalinase inhibitor can be directly mixed or indirectly connected through hydrogen bonds, and a co-crystallized sodium hydrate prepared through hydrogen bond connection is more stable in property and significant in pharmacokinetic property; although the action mechanism of the angiotensin receptor antagonist and the action mechanism of the enkephalinase inhibitor are different, the compound prepared from the angiotensin receptor antagonist and the enkephalinase inhibitor has an unexpected synergistic effect and has a positive application prospect in the anti-heart-failure and anti-hypertension treatment field.

The invention discloses hypertension treatment equipment comprising an automatic pressure supply device, a pneumatic pump, a pressure air sac and a tremolo, wherein the automatic pressure supply device is used for simultaneously or respectively automatically distributing pressure to multiple groups of objects; the pneumatic pump is connected with the automatic pressure supply device and supplies high-pressure gas to the automatic pressure supply device; the pressure air sac is a seal software device connected with the automatic pressure supply device and is used for mainly holding the high-pressure gas which is supplied by the pneumatic pump and is treated by the automatic pressure supply device; and the tremolo is a vibration massaging device flexibly stuck to the wall of the pressure air sac. By the technical scheme, the invention solves the problems that the side effect is very big because drugs need to be taken for life in treating hypertension and the treatment effect is slow and is not obvious and the time is long by adopting the common electrotherapy, magnet therapy and the like. The invention can make hypertension patients break away from the dependence of taking the drugs all the year, changes the current situation that the effect is slow and is not obvious and the treatment time is long by adopting the common electrotherapy, magnet therapy and the like and can control the blood pressure to be normal through the hypertension treatment equipment.

The invention discloses an application of a mussel protein antihypertensive peptide. The antihypertensive peptide has antihypertensive activity and is characterized in that an amino acid sequence of the antihypertensive peptide is Val-Ser-Trp-Pro-Cys-Arg-Trp(VSWPCRW); the molecular weight determined by ESI-MS (electrospray ionization mass spectrometry) is 935.07Da. The active peptide Val-Ser-Trp-Pro-Cys-Arg-Trp is obtained by shelling mussels, taking the meat of the mussels, carrying out enzymolysis on the meat, carrying out ultrafiltration on the enzymatic hydrolysate, adsorbing the enzymatic hydrolysate with an agarose magnetic microsphere immobilized ACE (angiotensin converting enzyme) and carrying out purification by RP-HPLC (reversed-phase high-performance liquid chromatography). The active peptide prepared by the invention has obvious ACE inhibitory activity and can be used in hypertension treatment related drugs.